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Rationale: Patient-reported outcomes provide new insights into the dynamics of asthma
management. Further to asthma control and quality of life, self-reported side effects of treat-
ment can be assessed with the validated Inhaled Corticosteroid Questionnaire (ICQ).
Objectives: To compare patient-reported side effects between the inhaled corticosteroids
ciclesonide and fluticasone propionate.
Methods: Patients with moderate or moderate-to-severe asthma, pre-treated with a constant
dose and type of medication, were randomized in three separate studies: 1) once daily cicle-
sonide 320 mg (nZ 234) or twice daily fluticasone propionate 200 mg (nZ 240); 2) twice daily
ciclesonide 320 mg (n Z 255) or twice daily fluticasone propionate 375 mg (n Z 273); and 3)
twice daily ciclesonide 320 mg (n Z 259) or twice daily fluticasone propionate 500 mg
(n Z 244). Patients rated the side effect questions of the 15 domain ICQ on a 7-point Likert
scale (0 Z not at all, 6 Z a very great deal) during scheduled visits.
Results: The majority of side effect scores remained similar with ciclesonide but worsened
statistically significantly with fluticasone propionate from baseline to the end of the study
in within-treatment analyses. In between-treatment analyses of studies 1 and 3 ciclesonide
significantly improved total side effect scores (p < 0.025) and 14 out of 30 individual local
and systemic domain scores (p < 0.025) compared with fluticasone propionate. In Study 2,
although ciclesonide improved the majority of scores compared with fluticasone propionate
only ‘oropharyngeal itching’ reached statistical significance (p < 0.025, one-sided).) 50 3613532; fax: þ31 (0) 50 3619320.
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1826 T. van der Molen et al.Conclusion: Patient-perceived side effects differ depending on the type of inhaled corticoste-
roids used. Patients with moderate-to-severe asthma report less intense side effects assessed
with ICQ with ciclesonide than with fluticasone propionate.
Clinical trial registration: The reported trials were completed before July 1 2005 and, there-
fore, are not registered.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are accepted worldwide as the
recommended first-line treatment for persistent asthma of
all severities in both adults and children.1,2 However, many
patients perceive relatively mild side effects even with
low-dose ICS.3 Although patients often do not mention
these mild side effects during consultation, the conse-
quences of side effects are not trivial as quality of life can
be significantly affected4 and treatment compliance
reduced.5 The extent of patient-perceived side effects
related to ICS use is likely to be underestimated in daily
clinical practice.6,7
Today, patient-reported outcomes are increasingly
combined with traditional clinical data in order to form
a comprehensive assessment of how asthma treatment and
management can be tailored to patient-focused care.8,9
Patients’ perception of their quality of life and symptom
control can yield important information unattainable from
routine clinical testing and may provide evidence of
a treatment benefit from a patient’s perspective.9
Further to quality of life and asthma control ques-
tionnaires,8,10e12 the Inhaled Corticosteroid Questionnaire
(ICQ) has been developed to measure the prevalence and
intensity of patient-perceived side effects.3,13 The ICQ has
been validated, and its reliability, reproducibility and
responsiveness to increasing ICS dose have been repor-
ted.3,13,14 Recent clinical studies of ICS safety have shown
improved systemic and local safety profiles with ciclesonide
versus fluticasone propionate.15e20 We hypothesise that
patient-based outcomes could reveal more precisely the
side effect profile of ciclesonide compared with fluticasone
propionate from the perspective of the patient than
traditionally spontaneously reported side effects.21 Here
we present the findings from the first three clinical studies
comparing the patient-reported side effects of ciclesonide
with fluticasone propionate in patients with moderate or
moderate-to-severe asthma, as measured by the ICQ.
Methods
Patients
In three separate studies, patients aged 12e75 years with
a history of bronchial asthma, as defined by the American
Thoracic Society,22 for 6 months but otherwise in good
health were included if they had been pre-treated with
a constant dose and type of asthma medication (except
rescue medication). All participants had reversible airway
obstruction, i.e. an improvement in forced expiratory
volume in 1 s (FEV1) 12% of initial and 200 mL afterinhaling 200e400 mg salbutamol, prior to randomization.
Appendix 1 contains further information on inclusion and
exclusion criteria.
Study design
All studies had a multicentre, randomized, parallel-group
design (Table 1). Prior to randomization and at each
scheduled visit correct inhaler technique was reviewed. No
spacer device was used for study-drug administration.
Patients were randomized as follows: study 1) ciclesonide
(CIC) 320 mg once daily or fluticasone propionate (FP)
200 mg twice daily; study 2) CIC 320 mg twice daily or FP
375 mg twice daily; and study 3) CIC 320 mg twice daily or
FP 500 mg twice daily. CIC was administered via metered-
dose inhaler (MDI) in all studies. FP was administered via
dry powder inhaler (DPI) in Study 1 and via MDI in Studies 2
and 3. Patients were blinded to medication in Study 3.
Salbutamol (100 mg/puff) was used as rescue medication
throughout all studies. Suspected fungal infections of the
mouth or throat were confirmed in the laboratory. Patients
recorded treatment compliance in daily diaries. All studies
were performed in compliance with the Guidelines for Good
Clinical Practice and the Declaration of Helsinki in its
revised form (Somerset West 1996). The protocols were
approved by the relevant Independent Ethics Committee or
Institutional Review Board for each participating centre.
Before recruitment into the studies, all patients gave
written informed consent. For adolescents taking part in
the studies, their legal representative also gave written
informed consent.
For more information regarding the methodologies of
these studies, we refer the reader to the respective
publications.15,19,20
Patient-reported side effect assessment
The ICQ consists of 57 side effect-related questions grouped
into 15 domains covering both oropharyngeal and systemic
side effects (Appendix 2).13 Patients completed the ICQ at
baseline, and after 4 and 12 weeks of treatment in Study 1;
at baseline and after 8, 16 and 24 weeks of treatment in
Study 2; and during run-in, at baseline and after 4, 8, 12,
16, 20 and 24 weeks of treatment in Study 3. At all time
points, patients assessed their experiences with asthma
medications over the previous 2 weeks.
Patients rated the questions on a 7-point Likert scale
from 0 (not at all) to 6 (a very great deal). The scoring rules
recommended by the ICQ authors were followed.23 The raw
scores of the ICQ were transformed into 15 domain scores
on a scale from 0 (none) to 100 (worst possible). All
Table 1 Summarized study details and selected baseline and patient characteristics of the intention-to-treat population in
the three studies.
Study 1 (N Z 474) Study 2 (N Z 528) Study 3 (N Z 503)
Run-in period (weeks) 1e4 2 2
Run-in medication FP 250 mg, or equivalent FP 500e1000 mg, or equivalent BDP 1000 mg, or equivalent


















CIC 320 mg twice daily FP 500 mg twice daily
Sex (n):
Female 144 146 158 164 136 125
Male 89 93 97 109 123 119












491  173 506  201 1125  378 1146  408 1376  556 1385  537
CIC administered via MDI in all studies (CIC 320 mg ex-actuator equivalent to CIC 400 mg ex valve); FP administered via DPI in Study 1 (FP
200 mg twice daily is equivalent to a total nominal daily dose of FP 400 mg) and MDI in Studies 2 (FP 375 mg ex valve equivalent to FP 330 mg
ex-actuator) and 3 (FP 500 mg ex valve equivalent to FP 440 mg ex-actuator).
a Data are presented as median (range).
b Data are presented as mean  standard deviation.
c Beclometasone dipropionate equivalent. CIC Z ciclesonide; FP Z fluticasone propionate; BDP Z beclomethasone dipropionate;
MDIZmetered-dose inhaler; DPIZ dry powder inhaler; FEV1Z forced expiratory volume in 1 s; T0Z randomization-to-treatment visit.
Patient-reported side effects of inhaled steroids 1827returned questionnaires were checked for missing
responses that were, where possible, completed by
patients during their visit.
Statistical analyses
Least squares means were calculated for each of the 15
domains in each study. In Studies 1 and 2, if non-inferiority
(non-inferiority margin for ICQ: þ4, one-sided p < 0.025,
per-protocol analysis) of CIC in comparison with FP was
demonstrated, then superiority (one-sided p < 0.025,
intention-to-treat [ITT] analysis) of CIC versus FP was
tested. In Study 3, superiority of CIC versus FP was tested.
Comparison of total and domain scores with baseline scores
were performed with an analysis of covariance analogous to
that used by Ebbut and Frith.24 The overall level of signif-
icance was 5%, two-sided (type _ error of a Z 0.05), which
in case of a one-sided hypothesis corresponds to 2.5%.
Therefore, within-treatment differences were significant if
p < 0.05 and between-treatment differences if p < 0.025.
The ICQ questionnaire was not a primary outcome and no
prospective power analysis was performed.
Results
In all three studies asthma control was maintained in both
the CIC and FP groups; for additional results we refer the
reader to the published clinical studies for the efficacy and
investigator-recorded safety results.15,19,20Patients
Baseline and patient characteristics were similar between-
treatment groups for each of the three studies (Table 1). Of
the 637 patients enrolled in Study 1, 474 were randomized
to treatment and the ITT population for ICQ assessment
consisted of 452 patients (CIC, n Z 224; FP, n Z 228). In
Study 2, of 658 patients enrolled, 528 patients were
randomized to treatment and 498 patients were evaluated
(CIC, n Z 244; FP, n Z 254). In Study 3, of 614 patients
enrolled, 503 were randomized (CIC, nZ 259; FP, nZ 244)
and 487 patients were evaluated (CIC, n Z 250; FP,
n Z 237). Median treatment compliance was 100% in both
treatment groups in all three studies.
Patient-reported side effect assessment
Results are presented sequentially by study. Within-treat-
ment results reflect changes in patient-perceived side
effects from baseline over the treatment period, as pre-
sented in Table 2 and Fig. 1. Between-treatment results
reflect differences in patient-perceived side effects asso-
ciated with CIC versus FP over the treatment period, and
are presented in Figs. 2 and 3. Key results are summarized
in Table 3. Positive within- or between-treatment differ-
ences correspond to increases in patient-reported side
effects.
Non-inferiority of CIC versus FP was demonstrated for
the total ICQ score and all domain scores in both Studies 1
Table 2 Within-treatment differences in total patient-reported side effect scores from baseline to the end of the study.
n LS mean  SE 95% CI p-Value(two-sided)
Study 1
CIC 320 mg once daily 224 0.38  0.61 0.82, 1.58 0.54
FP 200 mg twice daily 228 2.90  0.60 1.72, 4.09 <0.0001
Study 2
CIC 320 mg twice daily 244 1.27  0.72 0.15, 2.69 0.08
FP 375 mg twice daily 254 2.77  0.71 1.38, 4.17 0.0001
Study 3
CIC 320 mg twice daily 250 1.06  0.56 2.16, 0.04 0.06
FP 500 mg twice daily 237 0.99  0.57 0.14, 2.12 0.08
p-Values are significant if p < 0.05 vs baseline. Intention-to-treat population. Positive within-treatment differences correspond to an
increase in patient-reported side effects. LS Z least squares; SE Z standard error of the LS mean; CI Z confidence interval;
CIC Z ciclesonide; FP Z fluticasone propionate.
1828 T. van der Molen et al.and 2 and, therefore, superiority data are reported herein.
In the first analysis of the confirmatory testing procedure of
Study 3, superiority of CIC versus FP was not shown for the
primary variable ‘proportion of patients with local
oropharyngeal adverse events’. Therefore, superiority of
CIC over FP was tested in an exploratory manner in Study 3.
Study 1 (ciclesonide 320 mg once daily vs fluticasone
propionate 200 mg twice daily; 12 weeks)
Within-treatment results
There was no significant change from baseline to the end of
the study in the total score (Table 2) or the majority of
domain scores within the CIC 320 mg once daily group, with
the exception of a significant worsening for ‘perspiration’
and ‘skin hair nails’ (p < 0.05; Fig. 1a). FP 200 mg twice
daily resulted in a significant worsening from baseline in the
total score (p < 0.0001; Table 2) and the majority of
domain scores (p < 0.05; Fig. 1a). There was no significant
change in scores for ‘mood problems’, ‘dental deteriora-
tion’ and ‘oropharyngeal itching’ in the FP 200 mg twice
daily group.
Between-treatment results
Compared with FP 200 mg twice daily treatment, the change
in ICQ total score was significantly different with CIC 320 mg
once daily, resulting in a significant improvement, i.e.
a lower, total score (p Z 0.0011, one-sided; Fig. 2). For
eight domains e ‘oral candidiasis’, ‘oropharynx problems’,
‘taste disruption’, ‘unpleasant taste’, ‘vision deteriora-
tion’, ‘voice problems’, ‘thirst’ and ‘tiredness’ e scores
were significantly improved in the CIC 320 mg once daily
group compared with the FP 200 mg twice daily group
(p < 0.025, one-sided; Fig. 3).
Study 2 (ciclesonide 320 mg twice daily vs fluticasone
propionate 375 mg twice daily; 24 weeks)
Within-treatment results
There was no significant change in the total score (Table 2)
or the domain scores in the CIC 320 mg twice daily group
from baseline to the end of the study, with the exception of
a significant worsening of the ‘perspiration’ and ‘voice
problems’ scores (p < 0.01; Fig. 1b). In the FP 375 mg twice
daily group, there was a significant worsening in total score
(p Z 0.0001; Table 2) and the majority of domain scores(p < 0.05; Fig. 1b), with the exception of ‘mood problems’,
‘dental deterioration’, ‘oropharynx problems’, ‘facial
oedema’ and ‘tiredness’ scores.
Between-treatment results
With the exception of a significant improvement in
‘oropharyngeal itching’ in the CIC 320 mg twice daily group
compared with the FP 375 mg twice daily group (p < 0.025,
one-sided), there was no significant difference between the
treatment groups for total (Fig. 2) or domain (Fig. 3) scores
in Study 2.
Study 3 (ciclesonide 320 mg twice daily vs fluticasone
propionate 500 mg twice daily; 24 weeks)
Within-treatment results
There was no significant change from baseline to the end of
the study in total score in the CIC 320 mg twice daily group
(Table 2). The scores for ‘mood problems’, ‘oropharynx
problems’, ‘oropharyngeal itching’ and ‘thirst’ all signifi-
cantly improved in the CIC group (p < 0.05; Fig. 1c), and
there was no significant change in the remainder of the
domain scores. There was no significant change in total
score (Table 2) or the majority of the domain scores in the
FP 500 mg twice daily group, with the exception of
a significant worsening in the scores for ‘perspiration’, ‘eye
dryness’ and ‘tiredness’ (p < 0.05; Fig. 1c).
Between-treatment results
The change in total score was significantly different in the
CIC 320 mg twice daily group compared with the FP 500 mg
twice daily group (p Z 0.0047, one-sided; Fig. 2), with the
CIC group showing an improvement compared with FP
treatment. In addition, scores for ‘oropharyngeal itching’,
‘perspiration’, ‘eye dryness’, ‘voice problems’, ‘thirst’ and
‘tiredness’ were significantly improved with CIC compared
with FP (p < 0.025, one-sided; Fig. 3). There was no
significant difference between the treatment groups for the
remaining domain scores.
Discussion
We used the validated ICQ3,13 to assess patient-reported
side effects in patients with moderate and moderate-to-
severe asthma treated with CIC or FP in three randomized,
Figure 1 Within-treatment differences in individual domains
of patient-perceived side effect scores from baseline to the
end of the study. *p < 0.05 versus baseline. Intention-to-treat
population data: n Z 221e224 and 225e228 in Study 1,
240e244 and 251e254 in Study 2, and 248e250 and 231e237 in
Study 3 for CIC and FP, respectively. Positive within-treatment
differences correspond to an increase in patient-reported side
effects. CIC Z ciclesonide; FP Z fluticasone propionate;
LS Z least squares; SE Z standard error of the LS mean.
Patient-reported side effects of inhaled steroids 1829controlled clinical studies. Together, these studies showed
very few significant overall changes in patient-perceived
side effects during the study when CIC was used (four
domains significantly improved and four significantly wors-
ened). In contrast, these studies showed significant wors-
ening with FP (no domains significantly improved and 12, 10
and three domains significantly worsened in Studies 1, 2
and 3, respectively). Comparing CIC and FP, CIC treatment
provided significant improvements in the total score, as
well as in individual systemic and local side effect domains,
in two of the three studies (eight and six domains in Studies
1 and 3, respectively). In Study 2, only ‘oropharyngeal
itching’ significantly improved with CIC compared with FP.
These results are supported by studies demonstrating
a lower systemic and local side effect profile of CIC
compared with FP using the standard open question for
spontaneous side effects reporting.15e20 This highlights the
need for physicians to be aware of patient-perceived side
effects when prescribing ICS or when considering switching
between ICS treatments. Such patient-perceived side
effects can result in reduced compliance with treatment5,25
and, subsequently, in suboptimal asthma control. The doses
of ciclesonide and fluticasone investigated in the current
studies were found to be equivalent for efficacy and are
also in a similar range of estimated equipotent doses
according to the GINA guidelines.15,19,20 We, therefore,
believe it is reasonable to compare patient-perceived side
effects across the current doses.
Since systemic side effects are related to both the
pharmacodynamic characteristics of the drug and drug
deposition, it is difficult for physicians to choose the best
possible combination of ICS and inhaler device when
a patient reports systemic side effects. In all three studies
reported here, there was a clear trend or a significant
difference for at least one systemic domain in favour of
CIC. Systemic side effects associated with long-term ICS use
may include cataracts and glaucoma.26,27 Interestingly,
‘vision deterioration’ significantly worsened with FP treat-
ment in Studies 1 (12 weeks) and 2 (24 weeks), and CIC was
significantly superior to FP for this side effect in Study 1
(12 weeks). In addition, higher ICS doses have been related
to increased psychological side effects.28,29 Therefore, it
may be important from a patient’s perspective to switch
from a dose of beclomethasone dipropionate 1000 mg/day
or equivalent, as used by patients prior to study enrolment,
to, for example, CIC 640 mg/day, as the ‘mood problems’
domain was significantly improved in the CIC treatment
group in Study 3.
Together with the ICQ data, the studies reported here
also collected investigator-recorded spontaneous side
effect data that have been published elsewhere.15,19,20 This
gave us the opportunity to investigate whether patient-
reported and investigator-recorded side effects may differ.
In terms of local side effects, oral candidiasis did not occur
(0%) in the CIC group, whereas it was diagnosed in nine
patients (3.8%) in the FP group of Study 1, with a significant
difference between the groups.15 This is reflected in the
patient-reported side effect scores of Study 1 as assessed
by the ICQ, since the score for the question related to oral
candidiasis significantly worsened in the FP group from
baseline, but did not in the CIC group, and there was
a significant between-treatment difference. However,
Figure 2 Between-treatment differences in change of side effect perception (ciclesonideefluticasone propionate) in total
Inhaled Corticosteroid Questionnaire scores during the three studies. Differences were significant if p < 0.025 (one-sided).
Intention-to-treat population data: nZ 224 and 228 in Study 1, 244 and 254 in Study 2, and 250 and 237 in Study 3 for CIC and FP,
respectively. Positive between-treatment differences correspond to an increase in patient-reported side effects. LS Z least
squares; SE Z standard error of the LS mean; CIC Z ciclesonide; FP Z fluticasone propionate.
1830 T. van der Molen et al.despite significantly fewer local side effects being recorded
by the investigator with CIC compared with FP in Studies 2
(dysphonia and candidiasis)20 and 3 (candidiasis),19 the
improvement observed in patient-reported oral candidiasis
in the CIC group compared to FP group did not reach
statistical significance in these studies.Figure 3 Between-treatment differences in change in individual
study. *p < 0.025 CIC versus FP. Intention-to-treat population data:
Study 2, and 248e250 and 231e237 in Study 3 for CIC and FP, respe
an increase in patient-reported side effects. CIC Z ciclesonide; FP
error of the LS mean.A number of factors may have contributed to the wors-
ening in patient-reported side effects with FP treatment
from baseline to the end of the study. In Study 1, the dose
of ICS was higher during the treatment period than during
the run-in period in both the CIC and FP groups. In all three
studies, a switch to a different type of device or ICS maydomain Inhaled Corticosteroid Questionnaire scores during the
nZ 221e224 and 225e228 in Study 1, 240e244 and 251e254 in
ctively. Positive between-treatment differences correspond to
Z fluticasone propionate; LS Z least squares; SE Z standard
Table 3 Summary of within- and between-treatment differences in patient-reported side effect scores across the three
studies.
Study 1
CIC 320 mg once daily
vs FP 200 mg twice daily
Study 2
CIC 320 mg twice daily
vs FP 375 mg twice daily
Study 3
CIC 320 mg twice daily
vs FP 500 mg twice daily
Within-CIC-group differencesa
Total score worsened Not significant Not significant Not significant
Total score improved Not significant Not significant Not significant
Domain scores worsened (n) 2 2 None
Domain scores improved (n) None None 4
Within-FP-group differencesa
Total score worsened Significant Significant Not significant
Total score improved Not significant Not significant Not significant
Domain scores worsened (n) 12 10 3
Domain scores improved (n) None None None
Between-treatment differencesb
CIC total score superior to FP
total score
Significant Not significant Significant
CIC domain scores superior to
FP domain scores (n)
8 1 6
a Differences significant with p < 0.05 vs baseline.
b Differences significant with p < 0.025 vs FP; Intention-to-treat population data: nZ 221e224 and 225e228 in Study 1; 240e244 and
251e254 in Study 2; and 248e250 and 231e237 in Study 3 for CIC and FP, respectively; CICZ ciclesonide; FPZ fluticasone propionate.
Patient-reported side effects of inhaled steroids 1831have occurred and inhaler technique was reviewed at the
randomization-to-treatment visit and at each scheduled
visit thereafter, which possibly resulted in higher lung
deposition as the studies progressed. There were no data
prior to study entry to determine any changes in compli-
ance, but compliance was high during the treatment period
of all three studies, as is often the case in trial settings.30
These factors are likely to have been similar in the FP
and CIC treatment groups; however, the majority of
patient-reported side effects did not significantly worsen
from baseline to the end of the study with CIC treatment.
These studies, therefore, provide important information
from a patient’s perspective regarding the results of
switching between ICS treatments.
It is possible that different devices may account for
differences in patient-reported side effects seen between-
treatments in Study 1, in which CIC was delivered via MDI
versus FP via DPI, but not in Study 2 or 3 where MDI was
used in both arms. However, a previous placebo-controlled
study comparing both MDI and DPI devices of FP suggested
no differences between these devices in the investigator-
recorded side effects, dysphonia, oral candidiasis and
throat irritation, which were similar across all FP treatment
groups.31 In Study 3, the daily dose of FP was higher
(1000 mg ex valve) than the dose of CIC (640 mg ex
mouthpiece Z 880 mg ex valve), which may partly explain
the differences observed, although differences were still
observed in Study 1 and 2 where microgram doses were
similar. Finally, it cannot be ruled out that the open-label
design of Studies 1 and 2 may also have contributed to the
differences in patient-reported side effects seen between-
treatments.
The general limitations of all patient-reported ques-
tionnaires include respondent fatigue and measurement
bias. Limitations specific to the report of side effectsinclude the probability that the side effects experienced by
the patients included in the present studies are generally
mild, as patients have volunteered to participate and
continued to use their ICS regardless of their perceived side
effects.3 This so-called survival bias implies that patients in
real life may experience even more side effects than those
reported here and may benefit from prescription strategies
that aim to avoid side effects. Moreover, a quick and reli-
able patient-reported method for measuring side effects,
such as the ICQ, may encourage patients to become more
active in the management of their asthma; patient self-
management has been shown to improve quality of life and
compliance.32,33 In addition, patients are more likely to
report side effects when questioned specifically compared
with neutral questioning.34,35
In summary, patients with moderate and moderate-to-
severe asthma treated with CIC reported significantly less
intense side effects compared with patients of similar
severity treated with FP, as assessed by the ICQ.3,13 These
results mimic the results of the individual clinical studies
demonstrating an improved side effect profile assessed by
spontaneous side effect reporting of CIC in comparison with
FP but the assessment with the ICQ provides more detail
regarding the side effect profile.15e20 There is, therefore,
not only a need for physicians to be aware of patient-
perceived side effects with respect to the dose and the
application method but also the choice of the inhaled
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